TSMC's AI Capacity Crunch Confirmed, But Valuation and Execution Risks Loom

What happened

A Seeking Alpha article reports that TSMC's advanced 2nm and 3nm capacity and CoWoS packaging are fully sold out into 2027, underscoring its role as a critical AI semiconductor bottleneck. However, the DeepValue master report notes that this demand strength is already priced into the stock at a high 29.5x P/E, justifying a WAIT rating with an attractive entry near $320. The report highlights significant risks, including ~76% revenue concentration from top customers and margin dilution from overseas expansions and 2nm ramps. Market sentiment is crowded with a uniform AI narrative, making the stock vulnerable to any signs of demand digestion or execution delays. Investors should focus on the upcoming Apr 16 earnings call and monthly revenue prints to validate utilization trends and margin guidance against these risks.

Implication

The AI demand surge supports TSMC's revenue growth, but the current valuation at 29.5x P/E leaves little margin for error, with any utilization or margin slippage potentially driving significant downside. Risks such as overseas cost overruns or AI customer digestion could compress earnings, aligning with the bear case implied value of $250 and highlighting the fragility of the priced-in scenario. Management's ability to keep gross margin dilution within the stated 2-4% overseas and 2-3% 2nm frameworks is critical, as deviations would erode returns and challenge the investment case. High customer concentration amplifies volatility, with TSMC's own filings warning that AI demand may not be sustainable, necessitating close monitoring of monthly revenue trends. Therefore, while the long-term outlook is positive, near-term risk-adjusted returns are better served by adhering to the WAIT rating, using the Apr 16 call as a key data point for reassessment.

Thesis delta

The new article reinforces the AI demand narrative but does not alter the core investment thesis; it fails to address the valuation concerns and execution risks outlined in the DeepValue report, such as margin dilution and customer concentration. The recommendation remains to wait for either a lower price or confirmation from upcoming guidance that utilization is rising and margin headwinds are manageable, with no fundamental shift warranted.